Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

34.11 +0.16 (+0.48%)
Streaming Delayed Price Updated: 11:41 AM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 356,026
Open 34.47
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 33.95
Today's Range 34.06 - 34.47
52wk Range 27.95 - 43.32
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily

Performance

YTD
-13.13%
-13.13%
1 Month
-8.25%
-8.25%
3 Month
-10.49%
-10.49%
6 Month
-4.71%
-4.71%
1 Year
-18.29%
-18.29%

More News

Read More
AI To Revolutionize Clinical Trials And Diagnostics
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via FinancialNewsMedia
Exposures Product Safety
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
Via InvestorPlace
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Via The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
Via FinancialNewsMedia
Exposures COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Via Benzinga
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
From Genentech
Via Business Wire
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
Via Benzinga
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
Via Benzinga
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Via InvestorPlace
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Via Investor's Business Daily
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Via Benzinga
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Via Benzinga
Exposures Product Safety
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Via Benzinga
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
Via The Motley Fool
What's Going On With Sonnet BioTherapeutics Stock Today?
Via Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.